1 / 41

Acquired Heart Disease

Acquired Heart Disease. Mohammed Alghamdi, MD, FRCPC ( peds ), FRCPC (card), FAAP, FACC Assistant Professor and Consultant Pediatric Cardiology, Cardiac Science King Fahad Cardiac Centre King Saud University. Acquired Heart Disease. Rheumatic Fever Kawasaki Disease

isaura
Download Presentation

Acquired Heart Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Acquired Heart Disease Mohammed Alghamdi, MD, FRCPC (peds), FRCPC (card), FAAP, FACC Assistant Professor and Consultant Pediatric Cardiology, Cardiac Science King Fahad Cardiac Centre King Saud University

  2. Acquired Heart Disease • Rheumatic Fever • Kawasaki Disease • Infective Endocarditis • Pericarditis • Myocarditis • Cardiomyopathy • Cardiac Arrhythmias

  3. Rheumatic Fever • RF: most common cause of acquired heart disease in developing countries. • 150 in 100,000 in developing countries • 1 in 100,000 in developed countries. • Rheumatic heart disease (RHD) inflammatory changes to cardiac valves and myocardium.

  4. Rheumatic Fever • Precipitated by Group A Streptococcal (GAS) pharyngitis (not other types of GAS infections) • 2-4 weeks after untreated GAS Pharyngitis • T-cell and B-cell lymphocytes produce antibodies against some Streptococcal antigens that cross-react with antigens on myocytes or cardiac valve tissue.

  5. Jones criteria (1992) Rheumatic Fever Evidence of antecedent GAS infection 1. Positive throat culture or rapid antigen test for GAS 2. Raised or rising streptococcal antibody titre

  6. Rheumatic Fever Jones criteria (1992) • Two majors or one major and two minors plus evidence of antecedent GAS infection • Exceptions: • Chorea & indolent carditis do NOT require evidence of antecedent GAS infection • Recurrent episode requires : • Only one major OR • Several minor manifestations • Plus evidence GAS infection

  7. Rheumatic Fever • Arthritis: • Most common ARF presentation (75% of first attacks) • Migratory, Asymmetrical, Polyarthritis, of large joints • Typically: extremely painful • Highly responsive to salicylate and NSAID therapy • Within 3 days • Monoarthritisif history of early use of NSAID • Premature abortion the polyarthritis manifestation.

  8. Rheumatic Fever • Cardiatis: • Valvulitis: • MV / MV plus AoV /AoV • Early disease leads to valvular regurgitation, • prolonged or recurrent attacks lead stenosis • Pericarditis and myocarditis may occur

  9. Rheumatic Fever • Sydenham’s chorea • Jerky, uncoordinated movements esp. of hands, feet, tongue and face. • Disappear during sleep • More common in adolescence female • Occur after a prolonged latent period following GAS • 6 wks - 3 yrs following GAS infection • Strong association with carditis

  10. Rheumatic Fever • Erythemamarginatum • Rare & difficult to detect esp. in dark-skin patients • Circular patterns of bright pink macules or papules that blanch under pressure • Trunk and proximal extremities • Almost never on face • Not itchy or painful

  11. Rheumatic Fever • Subcutaneous nodules • Rare < 2% of cases • Highly specific manifestation of ARF • Round, firm, mobile and painless nodules • Appear 1-2 weeks after onset of other symptoms • last 1-2 weeks (rarely > 1 month) • Strongly associated with carditis

  12. Rheumatic Fever • Treatment: • Antibiotics to eradicate of residual GAS bacteria • Anti-inflammatory agents • High dose aspirin • Steroids for severe carditis • CHF therapy as indicated • Sydenham Chorea: • haloperidol

  13. Secondary Prophylaxis Rheumatic Fever

  14. Rheumatic Fever Duration of Secondary Prophylaxis

  15. Kawasaki Disease • KD: inflammatory disease of unknown etiology causing acute, diffuse vasculitis of medium size blood vessels (mainly coronary arteries). • Most common cause of acquired heart diseases in developed countries. • More common in Japanese population • Higher in males than females • Typical age: 6 months - 5 years

  16. Kawasaki Disease • Cardiac Involvement: • Coronary arteries: • Dilation and aneurysm formation • Thrombus formation • Fibrosis and stenosis • Myocardial infarction. • May cause myocarditis and endocarditis • Other medium size arteries • Auxiliary, femoral, iliac, and renal arteries

  17. Kawasaki Disease • Fever:at least 5 days duration • At least 4 of the following: • Conjunctivitis:bilateral, non-purulent • Skin Rash: polymorphous skin rash • Mucous membrane changes:red, dry, and cracked lips, strawberry tongue • Extremities changes:palms/soles erythema, hands/ feet edema, Skin peeling • Cervical lymphadenopathy:unilateral and >1.5 cm in diameter

  18. Kawasaki Disease • DDX of KD: • Scarlet fever • EBV infection • Adenovirus infection • Staphylococcal scalded skin syndrome • Drug reactions • Stevens–Johnson syndrome.

  19. Kawasaki Disease • Atypical (incomplete) KD: • Cases of KD that do not fulfill diagnostic criteria. • More common in infants • Children with • Fever greater than 5 days • Two or three classic symptoms • Supporting laboratory abnormalities or echo evidence of coronary involvements • Should be treated as KD

  20. Kawasaki Disease • Labs abnormalities in KD: • Elevated ESR > 50 (70%) • Elevated C-reactive (50%) • CBC: • Neutropenia , leukocytosis (50%) • Nonspecific anemia • Thrombocytosis • Marker of KD • Not seen until 2nd week of the disease • Elevated liver transaminases (40%) • Low serum albumin level • Sterile pyuria (33%) • Aseptic meningitis (up to 50%).

  21. Kawasaki Disease • Treatments: • IVIG 2 g/kg • 2nd dose if persistent fever within 48 h of the initial dose • High dose of aspirin of 30–100 mg/kg/day. • Once afebrile: aspirin is decreased to 3–5 mg/kg/day • Echo at base line • Repeat echocardiogram at 6–8 weeks • If normal coronary arteries : aspirin can be stopped • If coronary artery abnormalities: long-term Rx with aspirin • Other anticoagulants if giant aneurysm of coronary arteries

  22. Infective Endocarditis • infection of the endocardial lining of the heart or cardiac vessels • Rare but with high mortality • Usually affect abnormal cardiac structure • Valvular disease • Septal defects • Presence of foreign material such as mechanical valves and patch material after surgical repair.

  23. Infective Endocarditis • Etiology: • Gram- positive bacteria: • > 90 % 0f bacterial case • Streptococci Viridans : most common infectious agent • Staphylococcal species – especially prosthetic valves. • Enterococci : less common pediatric age group. • Gram-negative bacteria: • < 10% of bacterial cases • Example: HACEK group • Haemophilus, Actinobacillus, Cardiobacterium, Eikenella and Kingella • Fungal – uncommon • Neonate, immunocompromised patients, prolonged antibiotic • 10% IE case: organisms cannot be identified.

  24. Infective Endocarditis • Clinical Features: • General: • Fever • Nonspecific manifestations • myalgias, arthralgias, headache, and general malaise • Cardiac: • New onset or worsening valvular regurgitation • Congestive heart failure • Heart block

  25. Infective Endocarditis • Clinical Features: • Extracardiac - septic embloism: • CNS: infraction, brain abscess • Renal: proteinuria, hematuria, pyuria • PHx - Stigmata of SBE: • Janewaylesions:Non-tender, flat lesions on palms and soles. • Osler’s nodes: Tender, raised nodules on fingers and toes. • Roth’s spots: Exudative lesions of the retina. • Splinter hemorrhages: Non-blanching, linear, under nails. • Splenomegaly

  26. Infective Endocarditis Diagnostic Criteria - modified Duke criteria

  27. Infective Endocarditis • Labs: • Blood cultures are the most important lab test • Three blood cultures collected over a 24-h period • CBC: • Anemia • Elevated ESR/CRP • Positive rheumatoid factor

  28. Infective Endocarditis • Treatment: • Supportive medical therapy • Prolonged antibiotic therapy • Initially empiric broad spectrum Abx which then adjusted according to organism sensitivity. • 4-8 weeks course depending on the type of organism and resistance. • Removal of infected line • Surgical intervention: may be required

  29. Infective Endocarditis • SBE prophylaxis: • Only indicated at dental procedures for high risk patients • No longer recommended for GI or GU procedures • Prophylaxis regimens: • Oral amoxicillin 50 mg/kg (up to 2 g) OR • IV/IM ampicillin 50 mg/kg • Patients allergic to penicillin • Cephalexin 50 mg/kg PO (up to 2 g) OR • Clindamycin 20 mg/kg (up to 600 mg) OR • Azithromycin (or clarithromycin) 15 mg/kg (up to 500 mg)

  30. Infective Endocarditis

  31. Myocarditis • Inflammatory infiltrate of the myocardium with necrosis/degeneration of the myocytes • Viral infections: most common causes • Coxsackievirus type B • Adenovirus • Parvovirus B19 • Others: CMV, EBV, HIV, Hep C • Other infectious causes: bacteria, rickettsiae, protozoa. • Non-infectious causes: • Rheumatologic disease: SLE, rheumatoid arthritis • Drugs and Toxins: chemotherapy

  32. Myocarditis • Variable initial presentation • Viral prodrome: fever, URTI or GI symptoms • Hx: lethargy, poor feeding, irritability, respiratory distress, exercise intolerance • PHx: • Signs of CHF • Tachycardia • Tachypnia (increase work of breathing) • Gallop rhythm and murmur of mitral regurgitation • Hepatomegaly

  33. Myocarditis • Investigation: • CXR: • Cardiomegaly • Pulmonary congestion • ECG: • Sinus tachycardia • Low voltage ORS • Non-specific T wave changes • Echo: • Dilated LV with reduced systolic function • MR • Pericardial effusion

  34. Myocarditis • Investigation: • Myocardial biopsy: • Historically used to be the gold standard test • Currently not routinely performed • Invasive • low sensitivity of the procedure (3–63%) • patchy involvement of the myocardium • Treatment: • Supportive • Inotropes, Ventilation, ECMO • Anti-CHF therapy • IVIG and Steroid – not supporting evidence for their benefit • Antiviral agents and interferon – need further studies.

  35. Cardiomyopathy • Cardiomyopathy: myocardial disease resulting in thickening of myocardial fibers or fibrosis. • Pediatric cardiomyopathy: almost exclusively non- ischemic • Types: • Dilated cardiomyopathy (58%) • Hypertrophic cardiomyopathy (30%) • Restrictive cardiomyopathy (5%) • Arrhythmogenic Right Ventricular Cardiomyopathy ARVC (5%)

  36. END

More Related